Soleno Therapeutics, Inc. $SLNO Stake Increased by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 320.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,739 shares of the company’s stock after buying an additional 93,536 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Soleno Therapeutics were worth $8,297,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Soleno Therapeutics by 12.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,807,149 shares of the company’s stock valued at $189,763,000 after acquiring an additional 319,317 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Soleno Therapeutics by 52.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 407,444 shares of the company’s stock valued at $27,543,000 after purchasing an additional 140,779 shares during the period. State of New Jersey Common Pension Fund D bought a new position in Soleno Therapeutics during the third quarter valued at about $2,060,000. TimesSquare Capital Management LLC boosted its stake in Soleno Therapeutics by 52.6% during the third quarter. TimesSquare Capital Management LLC now owns 377,566 shares of the company’s stock worth $25,523,000 after buying an additional 130,197 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Soleno Therapeutics by 1.4% during the third quarter. Rhumbline Advisers now owns 59,860 shares of the company’s stock valued at $4,047,000 after acquiring an additional 814 shares during the period. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Stock Up 0.3%

SLNO opened at $38.61 on Thursday. Soleno Therapeutics, Inc. has a twelve month low of $36.67 and a twelve month high of $90.32. The company’s 50-day moving average price is $44.04 and its two-hundred day moving average price is $55.43. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -20.98 and a beta of -3.16. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10.

Analyst Ratings Changes

SLNO has been the subject of a number of recent research reports. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $120.00 price target (up previously from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $114.00 price objective (up previously from $106.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Soleno Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $110.62.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.